Ironwood Pharmaceuticals takes a stand against gastrointestinal ailments and other medical conditions. The firm develops internally discovered gastrointestinal drugs; its first commercial product, Linzess (or linaclotide), a treatment for irritable bowel syndrome (IBS) and chronic constipation, is sold in the US and in Canada under the brand name Constella. Linzess was developed with partner Forest Laboratories, which shares US marketing rights. Outside of the US, Ironwood licensed development and commercialization rights for the drug to Almirall in Europe and other partners in Asia. The firm also has products in development for other gastrointestinal, central nervous system (CNS), and inflammatory conditions.